A citation-based method for searching scientific literature

N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote, T Baert, I Belaroussi, A Dashora, S Olbrecht, F Planchamp, D Querleu. Ann Oncol 2019
Times Cited: 207







List of co-cited articles
505 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
141
3

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan,[...]. Lancet 2016
129
3

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
C K Lee, R J Simes, C Brown, V Gebski, J Pfisterer, A-M Swart, D Berton-Rigaud, M Plante, T Skeie-Jensen, I Vergote,[...]. Ann Oncol 2013
24
12

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A N Gordon, J T Fleagle, D Guthrie, D E Parkin, M E Gore, A J Lacave. J Clin Oncol 2001
873
3

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Gavin C E Stuart, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander, Jonathan Ledermann, Christian Marth, Tate Thigpen, Edward Trimble. Int J Gynecol Cancer 2011
273
3

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik, Alain G Zeimet, Harald Sommer, Peter Klare, Martina Stauch, Axel Paulenz, Oumar Camara, Elke Keil,[...]. J Clin Oncol 2008
101
3

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.
J McGee, M Bookman, P Harter, C Marth, I McNeish, K N Moore, A Poveda, F Hilpert, K Hasegawa, M Bacon,[...]. Ann Oncol 2017
29
10

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Eric Pujade-Lauraine, Susana Banerjee, Sandro Pignata. J Clin Oncol 2019
26
11

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade-Lauraine, Sabino De Placido, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici,[...]. Lancet Oncol 2014
206
3

Newly diagnosed ovarian cancer: Which first-line treatment?
Domenica Lorusso, Valentina Ceni, Gennaro Daniele, Vanda Salutari, Antonella Pietragalla, Margherita Muratore, Camilla Nero, Francesca Ciccarone, Giovanni Scambia. Cancer Treat Rev 2020
6
50

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
S Banerjee, A M Oza, M J Birrer, E P Hamilton, J Hasan, A Leary, K N Moore, B Mackowiak-Matejczyk, J Pikiel, I Ray-Coquard,[...]. Ann Oncol 2018
28
10

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
David G Mutch, Mauro Orlando, Tiana Goss, Michael G Teneriello, Alan N Gordon, Scott D McMeekin, Yanping Wang, Dennis R Scribner, Martin Marciniack, R Wendel Naumann,[...]. J Clin Oncol 2007
266
3

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
313
3

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Weiva Sieh, Martin Köbel, Teri A Longacre, David D Bowtell, Anna deFazio, Marc T Goodman, Estrid Høgdall, Suha Deen, Nicolas Wentzensen, Kirsten B Moysich,[...]. Lancet Oncol 2013
228
3


The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Angela George, Jennifer McLachlan, Nina Tunariu, Chiara Della Pepa, Cristina Migali, Martin Gore, Stan Kaye, Susana Banerjee. BMC Cancer 2017
16
18

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
3

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006
3


Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Paulina Cybulska, Arnaud Da Cruz Paula, Jill Tseng, Mario M Leitao, Ali Bashashati, David G Huntsman, Tayyebeh M Nazeran, Carol Aghajanian, Nadeem R Abu-Rustum, Deborah F DeLair,[...]. Gynecol Oncol 2019
32
9

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
458
3

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.
David S P Tan, Marjan Iravani, W Glenn McCluggage, Maryou B K Lambros, Fernanda Milanezi, Alan Mackay, Charles Gourley, Felipe C Geyer, Radost Vatcheva, Joanne Millar,[...]. Clin Cancer Res 2011
89
2

Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature.
Dimitrios Nasioudis, Lakeisha Mulugeta-Gordon, Erin McMinn, Melissa K Frey, Eloise Chapman-Davis, Kevin Holcomb. Int J Gynecol Cancer 2020
6
33

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
B A Goff, R Sainz de la Cuesta, H G Muntz, D Fleischhacker, M Ek, L W Rice, N Nikrui, H K Tamimi, J M Cain, B E Greer,[...]. Gynecol Oncol 1996
272
2

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson. Gynecol Oncol 2018
26
7

Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
Martin Köbel, Steve E Kalloger, David G Huntsman, Jennifer L Santos, Kenneth D Swenerton, Jeffrey D Seidman, C Blake Gilks. Int J Gynecol Pathol 2010
224
2

Fertility-sparing surgery for early stage epithelial ovarian cancer.
Toyomi Satoh, Hiroyuki Yoshikawa. Jpn J Clin Oncol 2016
10
20

Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Toshio Takada, Haruko Iwase, Chiaki Iitsuka, Hidetaka Nomura, Kimihiko Sakamoto, Kohei Omatsu, Nobuhiro Takeshima, Ken Takizawa. Int J Gynecol Cancer 2012
23
8

Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?
Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Satoyo Hosono, Michiyasu Kawai, Tetsuro Nagasaka, Fumitaka Kikkawa. Hum Reprod 2011
40
5

Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?
Mika Mizuno, Hiroaki Kajiyama, Kiyosumi Shibata, Kimio Mizuno, Osamu Yamamuro, Michiyasu Kawai, Toru Nakanishi, Tetsuro Nagasaka, Fumitaka Kikkawa. Int J Gynecol Cancer 2012
19
10

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park,[...]. Cancer Res Treat 2020
8
25

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Masataka Takenaka, Martin Köbel, Dale W Garsed, Sian Fereday, Ahwan Pandey, Dariush Etemadmoghadam, Joy Hendley, Ayako Kawabata, Daito Noguchi, Nozomu Yanaihara,[...]. Clin Cancer Res 2019
11
18

Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Mitsutake Yano, Tomomi Katoh, Mariko Miyazawa, Masaki Miyazawa, Naoki Ogane, Maiko Miwa, Kosei Hasegawa, Hisashi Narahara, Masanori Yasuda. Sci Rep 2019
6
33


Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Seiji Mabuchi, Toru Sugiyama, Tadashi Kimura. J Gynecol Oncol 2016
61
3

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.
Yi Kan Wang, Ali Bashashati, Michael S Anglesio, Dawn R Cochrane, Diljot S Grewal, Gavin Ha, Andrew McPherson, Hugo M Horlings, Janine Senz, Leah M Prentice,[...]. Nat Genet 2017
114
2

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
Michael S Anglesio, Ali Bashashati, Yi Kan Wang, Janine Senz, Gavin Ha, Winnie Yang, Mohamed R Aniba, Leah M Prentice, Hossein Farahani, Hector Li Chang,[...]. J Pathol 2015
77
2

The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
Liat Hogen, Gillian Thomas, Marcus Bernardini, Dina Bassiouny, Harinder Brar, Lilian T Gien, Barry Rosen, Lisa Le, Danielle Vicus. Gynecol Oncol 2016
16
12

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
Paul J Hoskins, Nhu Le, Blake Gilks, Anna Tinker, Jennifer Santos, Frances Wong, Kenneth D Swenerton. J Clin Oncol 2012
72
2

Clear cell carcinoma of the ovary: a review of the literature.
Marcela G del Carmen, Michael Birrer, John O Schorge. Gynecol Oncol 2012
143
2

Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Masashi Takano, Hiroshi Tsuda, Toru Sugiyama. J Exp Clin Cancer Res 2012
51
3

Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary.
Oluwole Fadare, Vinita Parkash. Surg Pathol Clin 2019
17
11

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, Hirofumi Michimae, Eizo Kimura, Daisuke Aoki, Toshiko Jobo, Shoji Kodama, Fumitoshi Terauchi,[...]. Lancet Oncol 2013
271
2

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
David R Crotzer, Charlotte C Sun, Robert L Coleman, Judith K Wolf, Charles F Levenback, David M Gershenson. Gynecol Oncol 2007
100
2

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
D S Chi, E L Eisenhauer, J Lang, J Huh, L Haddad, N R Abu-Rustum, Y Sonoda, D A Levine, M Hensley, R R Barakat. Gynecol Oncol 2006
405
2

Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.
Yoo-Young Lee, Tae-Joong Kim, Min-Ji Kim, Ha-Jeong Kim, Taejong Song, Min Kyu Kim, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Byoung-Gie Kim. Gynecol Oncol 2011
56
3

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Toru Sugiyama, Aikou Okamoto, Takayuki Enomoto, Tetsutaro Hamano, Eriko Aotani, Yasuhisa Terao, Nao Suzuki, Mikio Mikami, Nobuo Yaegashi, Kiyoko Kato,[...]. J Clin Oncol 2016
72
2

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord,[...]. Gynecol Oncol 2017
35
5

Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
T Kita, Y Kikuchi, K Kudoh, M Takano, T Goto, J Hirata, T Tode, I Nagata. Oncol Rep 2000
36
5



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.